< span lang =“en”>销售抗原测试COVID-19预计失败< / span > < / > < span lang =“en”>关于ο检测,而< / span > < a href = " https://avacta.com/update-on-uk-availability-of-affidx-sars-cov-2-lateral-flow-rapid-antigen-test-following-implementation-of-ctda-regulations/ " target = "平等"风格= " background: rgb (255, 255, 255);“> < span lang =“en”>一些融通的销售必须暂停由于减少敏感性< / span > < / > < span lang =“en”>。适配子集团提供其optim粘合剂诊断开发人员启用新的诊断化验和改善当前COVID-19诊断的敏感性来支持持续的大流行。< / span > < / p > < p > < span lang =“en”> < br > < / span >目前使用optim粘合剂在DeepVerge成功的临床验证Microtox <一口>®< /一口> PD SARS-CoV-2的检测废水的平台。Microtox PD使用生物传感器技术,使SARS-CoV-2 S1 optim粘合剂,捕获和检测病毒突起蛋白特异性为100%。 The real-time detection of even miniscule concentrations (femtograms/mL) of COVID-19 in wastewater ensures outbreaks can be detected up to a week ahead of health facility testing.

Proof-of-concept work performed by LFT developers, Lateral Dx, working with the Optimer binder has shown that it performs well when used as part of hybrid matched pair with an antibody, which could help to enable reformatting of current tests or new LFT assays to address the pandemic.

Arron Tolley, Chief Executive Officer of Aptamer Group, commented: “Optimer binders are being explored by our partners across the diagnostic industry for a range of conditions, such as lung infection and inflammation. With their excellent target recognition, consistent supply and temperature stability that enables simple global logistics, Optimer-based tests provide an excellent antibody alternative for use in diagnostics. Most recently, Aptamer Group is pleased to be able to offer its proprietary Optimer binder to enable diagnostic developers to increase the sensitivity of current tests and for the development of new tests for COVID-19 infection, specifically for the Omicron variant.”

  

">